Literature DB >> 14711065

Obesity and dyslipidemia.

Barbara V Howard1, Giacomo Ruotolo, David C Robbins.   

Abstract

The primary dyslipidemia related to obesity is characterized by increased triglycerides, decreased HDL levels, and abnormal LDL composition. Much work has been done to elucidate the pathogenesis of the dyslipidemia of obesity, which seems to be closely related to insulin resistance in obese individuals; however, more studies in humans are needed to further understand the metabolic mechanisms underlying the changes, and to distinguish between the roles of insulin resistance and body fat in the lipoprotein changes. The dyslipidemia associated with obesity no doubt plays a major role in the development of atherosclerosis and CVD in obese individuals. All of the components of the dyslipidemia, including higher triglycerides, decreased HDL levels, and increased small, dense LDL particles, have been shown to be atherogenic. Weight loss and exercise, even if they do not result in normalization of body weight, can improve this dyslipidemia and thus reduce CVD risk. In addition, obese individuals should be targeted for intense lipid-lowering therapy, when necessary.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711065     DOI: 10.1016/s0889-8529(03)00073-2

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  76 in total

1.  Dysmetabolic Signals in "Metabolically Healthy" Obesity.

Authors:  Peter Manu; Constantin Ionescu-Tirgoviste; James Tsang; Barbara A Napolitano; Martin L Lesser; Christoph U Correll
Journal:  Obes Res Clin Pract       Date:  2012-01       Impact factor: 2.288

2.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

3.  Postpartum lipid levels in women with major depression.

Authors:  Beth A Prairie; Stephen R Wisniewski; James F Luther; Dorothy Sit; Katherine L Wisner
Journal:  J Womens Health (Larchmt)       Date:  2012-01-27       Impact factor: 2.681

Review 4.  Obesity and lipids.

Authors:  Wendy M Miller; Katherine E Nori-Janosz; Martin Lillystone; Jose Yanez; Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

5.  Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess.

Authors:  Bronwen Martin; Michele Pearson; Lisa Kebejian; Erin Golden; Alex Keselman; Meredith Bender; Olga Carlson; Josephine Egan; Bruce Ladenheim; Jean-Lud Cadet; Kevin G Becker; William Wood; Kara Duffy; Prabhu Vinayakumar; Stuart Maudsley; Mark P Mattson
Journal:  Endocrinology       Date:  2007-06-14       Impact factor: 4.736

6.  Predictors of Subclinical Inflammatory Obesity: Plasma Levels of Leptin, Very Low-Density Lipoprotein Cholesterol and CD14 Expression of CD16+ Monocytes.

Authors:  Fernanda Leite; Ângela Leite; Ana Santos; Margarida Lima; Joselina Barbosa; Marco Cosentino; Laura Ribeiro
Journal:  Obes Facts       Date:  2017-07-22       Impact factor: 3.942

Review 7.  Aggressive diets and lipid responses.

Authors:  Claudia Panzer; Caroline M Apovian
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

8.  Metabolic syndrome in carbon disulfide-poisoned subjects in Korea: does chemical poisoning induce metabolic syndrome?

Authors:  Hyung-Joon Jhun; Sang-Yoon Lee; Sang-Hyuk Yim; Mi-Jung Kim; Kyung-Keun Park; Sung-Il Cho
Journal:  Int Arch Occup Environ Health       Date:  2008-10-25       Impact factor: 3.015

Review 9.  Managing cardiovascular risk in overweight children and adolescents.

Authors:  Sarita Dhuper; Sujatha Buddhe; Sunil Patel
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 10.  Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Exp Gerontol       Date:  2009-07-19       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.